Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'FENOFIBRATE' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 130 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Nigon, F; Serfaty-Lacrosniere, C; Beucler, I; Chauvois, D; Neveu, C; Giral, P; Chapman, MJ; Bruckert, E
      Plant sterol-enriched margarine lowers plasma LDL in hyperlipidemic subjects with low cholesterol intake: Effect of fibrate treatment

      CLINICAL CHEMISTRY AND LABORATORY MEDICINE
    2. Guo, Q; Wang, PR; Milot, DP; Ippolito, MC; Hernandez, M; Burton, CA; Wright, SD; Chao, YS
      Regulation of lipid metabolism and gene expression by fenofibrate in hamsters

      BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
    3. Rabasa-Lhoret, R; Rasamisoa, M; Avignon, A; Monnier, L
      Rare side-effects of fenofibrate

      DIABETES & METABOLISM
    4. Sanoski, CA
      Part 1 of 2 - Update on dyslipidemia management: Emerging CHD risk factors, new evidence and strategies

      FORMULARY
    5. Song, JC; White, CM
      Do HMG-CoA reductase inhibitors affect fibrinogen?

      ANNALS OF PHARMACOTHERAPY
    6. Stulc, T; Melenovsky, V; Grauova, B; Kozich, V; Ceska, R
      Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy

      NUTRITION
    7. Milpied-Homsi, B
      Ketoprofene gel-induced allergy

      PRESSE MEDICALE
    8. Sundvold, H; Grindflek, E; Lien, S
      Tissue distribution of porcine peroxisome proliferator-activated receptor alpha: detection of an alternatively spliced mRNA

      GENE
    9. Yamamoto, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Hada, T
      Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol

      JOURNAL OF RHEUMATOLOGY
    10. Goffin, E; Devuyst, O; Pirson, Y
      Deterioration in renal function associated with fibrate therapy

      CLINICAL NEPHROLOGY
    11. Gajdos, M; Mongiellova, V; Huttova, D; Cibulova, L; Krivosikova, Z; Spustova, V; Dzurik, R
      Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    12. Durieu, C; Marguery, MC; Giordano-Labadie, F; Journe, F; Loche, F; Bazex, J
      Photoaggravated contact allergy and contact photoallergy to ketoprofen: 19cases

      ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE
    13. Tsutsumi, M; Takase, S
      Effect of fenofibrate on fatty liver in rats treated with alcohol

      ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
    14. Lossner, A; Banditt, P; Troger, U
      Rapid and simple method for detection of fenofibric acid in human serum byhigh-performance liquid chromatography

      PHARMAZIE
    15. Aguilar-Salinas, CA; Fanghanel-Salmon, G; Meza, E; Montes, J; Gulias-Herrero, A; Sanchez, L; Monterrubio-Flores, EA; Gonzalez-Valdez, H; Perez, FJG
      Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias:An open-label, multicenter study

      METABOLISM-CLINICAL AND EXPERIMENTAL
    16. Dierkes, J; Westphal, S; Kunstmann, S; Banditt, P; Lossner, A; Luley, C
      Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate

      ATHEROSCLEROSIS
    17. Bissonnette, R; Treacy, E; Rozen, R; Boucher, B; Cohn, JS; Genest, J
      Fenofibrate raises plasma homocysteine levels in the fasted and fed states

      ATHEROSCLEROSIS
    18. Tan, CE; Chew, LS; Tai, ES; Chio, LF; Lim, HS; Loh, LM; Shepherd, J
      Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control

      ATHEROSCLEROSIS
    19. Wang, PR; Qiu, G; Ippolito, M; Wu, M; Milot, D; Ventre, J; Doebber, T; Wright, SD; Chao, YS
      High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists

      EUROPEAN JOURNAL OF PHARMACOLOGY
    20. Nowicka, G; Jarosz, A
      LpAI in HDL subfractions: serum levels in men and women with coronary heart disease and changes under hypolipemic therapy

      CLINICA CHIMICA ACTA
    21. Fartoux-Heymann, L; Narcy-Lambare, B; Labayle, D; Fischer, D
      Acute hepatitis and toxidermia due to fencifibrate (Secalip (R))

      ANNALES DE MEDECINE INTERNE
    22. Muntau, AC; Mayerhofer, PU; Albet, S; Schmid, TE; Bugaut, M; Roscher, AA; Kammerer, S
      Genomic organization, expression analysis, and chromosomal localization ofthe mouse PEX3 gene encoding a peroxisomal assembly protein

      BIOLOGICAL CHEMISTRY
    23. Krempf, M; Rohmer, V; Farnier, M; Issa-Sayegh, M; Corda, C; Sirugue, I; Gerlinger, C; Masseyeff-Elbaz, MF
      Efficacy and safety of micronised fenofibrate in a randomised double-blindstudy comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia

      DIABETES & METABOLISM
    24. Albes, B; Marguery, MC; Schwarze, HP; Journe, F; Loche, F; Bazex, J
      Prolonged photosensitivity following contact photoallergy to ketoprofen

      DERMATOLOGY
    25. Broeders, N; Knoop, C; Antoine, M; Tielemans, C; Abramowicz, D
      Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

      NEPHROLOGY DIALYSIS TRANSPLANTATION
    26. Conilleau, V; Dompmartin, A; Michel, M; Verneuil, L; Leroy, D
      Photoscratch testing in systemic drug-induced photosensitivity

      PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE
    27. Levin, A; Duncan, L; Djurdjev, O; Shapiro, RJ; Frohlich, J; Belanger, A; Dumas, R; Ross, S
      A randomized placebo-controlled double-blind trial of lipid lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate

      CLINICAL NEPHROLOGY
    28. Liang, BH; McMaster, JC; Kroeger, EA; Hatch, GM; Mymin, D; Dembinski, T; Arthur, G; Shen, G; Man, RYK; Choy, PC
      The effect of fenofibrate treatment on endothelium-dependent relaxation induced by oxidative modified low density lipoprotein from hyperlipidemic patients

      MOLECULAR AND CELLULAR BIOCHEMISTRY
    29. Milionis, HJ; Elisaf, MS
      Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: Case histories

      CURRENT MEDICAL RESEARCH AND OPINION
    30. Guichard, JP; Blouquin, P; Qing, Y
      A new formulation of fenofibrate: Suprabioavailable tablets

      CURRENT MEDICAL RESEARCH AND OPINION
    31. Genest, J; Nguyen, NH; Theroux, P; Davignon, J; Cohn, JS
      Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    32. Pan, WJ; Gustavson, LE; Achari, R; Rieser, MJ; Ye, X; Gutterman, C; Wallin, BA
      Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers

      JOURNAL OF CLINICAL PHARMACOLOGY
    33. Kiortsis, DN; Millionis, H; Bairaktari, E; Elisaf, MS
      Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    34. Kozlov, SG; Lyakishev, AA; Tvorogova, MG
      Assessment of efficacy of fluvastatin and fenofibrate in patients with noninsulin-dependent diabetes with hypercholesterolemia and combined hyperlipidemia

      KARDIOLOGIYA
    35. Idzior-Walus, B; Sieradzki, J; Rostworowski, W; Zdzienicka, A; Kawalec, E; Wojcik, J; Zarnecki, A; Blane, G
      Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X

      EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
    36. Ugawa, T; Kakuta, H; Moritani, H; Matsuda, K; Ishihara, T; Yamaguchi, M; Naganuma, S; Iizumi, Y; Shikama, H
      YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species

      BRITISH JOURNAL OF PHARMACOLOGY
    37. Chaput, E; Saladin, R; Silvestre, M; Edgar, AD
      Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    38. Sprecher, DL
      Raising high-density lipoprotein cholesterol with niacin and fibrates: A comparative review

      AMERICAN JOURNAL OF CARDIOLOGY
    39. Feher, MD; Caslake, M; Foxton, J; Cox, A; Packard, CJ
      Atherogenic lipoprotein phenotype in type 2 diabetes: Reversal with micronised fenofibrate

      DIABETES-METABOLISM RESEARCH AND REVIEWS
    40. Bairaktari, ET; Tzallas, CS; Tsimihodimos, VK; Liberopoulos, EN; Miltiadous, GA; Elisaf, MS
      Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia

      JOURNAL OF CARDIOVASCULAR RISK
    41. Guay, DRP
      Micronized fenofibrate: A new fibric acid hypolipidemic agent

      ANNALS OF PHARMACOTHERAPY
    42. Dumortier, J; Slim, R; Chevallier, M; Boillot, O; Thaunat, JL; Vaillant, E; Vial, T; Bellemin, B; Paliard, P; Scoazec, JY
      Acute severe fibrosing hepatitis associated with ciprofibrate treatment

      GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE
    43. Kerc, J; Srcic, S; Knez, Z; Sencar-Bozic, P
      Micronization of drugs using supercritical carbon dioxide

      INTERNATIONAL JOURNAL OF PHARMACEUTICS
    44. Hottelart, C; El Esper, N; Achard, JM; Pruna, A; Fournier, A
      Fenofibrate increases creatininemia but does not alter glomerular filtration rate in patients with mild renal insufficiency

      NEPHROLOGIE
    45. Hunninghake, DB
      Pharmacologic management of triglycerides

      CLINICAL CARDIOLOGY
    46. Elisaf, M; Tsimichodimos, V; Bairaktari, E; Siamopoulos, KC
      Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    47. de Lorgeril, M; Salen, P; Bontemps, L; Belichard, P; Geyssant, A; Itti, R
      Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    48. Berger, J; Albet, S; Bentejac, M; Netik, A; Holzinger, A; Roscher, AA; Bugaut, M; Forss-Petter, S
      The four murine peroxisomal ABC-transporter genes differ in constitutive, inducible and developmental expression

      EUROPEAN JOURNAL OF BIOCHEMISTRY
    49. Beghin, L; Capps, N; Duhal, N; Davies, J; Staels, B; Luc, G
      Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate

      ANNALS OF CLINICAL BIOCHEMISTRY
    50. ASCAH KJ; ROCK GA; WELLS PS
      INTERACTION BETWEEN FENOFIBRATE AND WARFARIN

      The Annals of pharmacotherapy
    51. BOSCA F; MIRANDA MA
      PHOTOSENSITIZING DRUGS CONTAINING THE BENZOPHENONE CHROMOPHORE

      Journal of photochemistry and photobiology.B, Biology
    52. Bailey, DS; Bondar, A; Furness, LM
      Pharmacogenomics - it's not just pharmacogenetics

      CURRENT OPINION IN BIOTECHNOLOGY
    53. Lacroix, PM; Dawson, BA; Sears, RW; Black, DB; Cyr, TD; Ethier, JC
      Fenofibrate raw materials: HPLC methods for assay and purity and an NMR method for purity

      JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
    54. GANNECARRIE N; DELEUSSE A; GUETTIER C; CASTERA L; LEVECQ H; BERTRAND HJ; PLUMET Y; TRINCHET JC; BEAUGRAND M
      AUTOIMMUNE HEPATITIS ASSOCIATED WITH FIBRATE TREATMENT

      Gastroenterologie clinique et biologique
    55. NOBILIS M; KVETINA J; ANZENBACHER P; VONTOR T; SVOBODA D; BRATOVA M; SOLICHOVA D; ZADAK Z; BLAHA V; VLCEK J
      DISTRIBUTION OF FENOFIBRIC ACID IN LIPOPROTEIN FRACTIONS OF PATIENTS

      European journal of drug metabolism and pharmacokinetics
    56. Hertz, R; Bar-Tana, J
      Peroxisome proliferator-activated receptor (PPAR) alpha activation and itsconsequences in humans

      TOXICOLOGY LETTERS
    57. MILLER DB; SPENCE JD
      CLINICAL PHARMACOKINETICS OF FIBRIC ACID-DERIVATIVES (FIBRATES)

      Clinical pharmacokinetics
    58. Fukuda, N; Miyagi, C; Zhang, L; Jayasooriya, AP; Sakono, M; Yamamoto, K; Ide, T; Sugano, M
      Reciprocal effects of dietary sesamin on ketogenesis and triacylglycerol secretion by the rat liver

      JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY
    59. Tsoko, M; Beauseigneur, F; Gresti, J; Demarquoy, J; Clouet, P
      Hypolipidaemic effects of fenofibrate are not altered by mildronate-mediated normalization of carnitine concentration in rat liver

      BIOCHIMIE
    60. CHAPMAN MJ; GUERIN M; BRUCKERT E
      ATHEROGENIC, DENSE LOW-DENSITY LIPOPROTEINS - PATHOPHYSIOLOGY AND NEWTHERAPEUTIC APPROACHES

      European heart journal
    61. WILSON TW; ALONSOGALICIA M; ROMAN RJ
      EFFECTS OF LIPID-LOWERING AGENTS IN THE DAHL SALT-SENSITIVE RAT

      Hypertension
    62. MCLAUGHLIN PR; GLADSTONE P
      DIABETES ATHEROSCLEROSIS INTERVENTION STUDY (DAIS) - QUANTITATIVE CORONARY ANGIOGRAPHIC ANALYSIS OF CORONARY-ARTERY ATHEROSCLEROSIS

      Catheterization and cardiovascular diagnosis
    63. DOXEY DL; NARES S; PARK B; TRIEU C; CUTLER CW; IACOPINO AM
      DIABETES-INDUCED IMPAIRMENT OF MACROPHAGE CYTOKINE RELEASE IN A RAT MODEL - POTENTIAL ROLE OF SERUM-LIPIDS

      Life sciences (1973)
    64. STAELS B; AUWERX J
      REGULATION OF APO A-I GENE-EXPRESSION BY FIBRATES

      Atherosclerosis (Amsterdam)
    65. GAW A
      EVIDENCE BASED APPROACH FOR THE MANAGEMENT OF MIXED HYPERLIPIDEMIA

      Atherosclerosis (Amsterdam)
    66. HOLZINGER A; MUNTAU A; MAYERHOFER P; KAMMERER S; ALBET S; BUGAUT M; ROSCHER AA
      THE MOUSE GENE ENCODING THE PEROXISOMAL MEMBRANE-PROTEIN 1-LIKE PROTEIN (PXMP1-L) - CDNA CLONING, GENOMIC ORGANIZATION AND COMPARATIVE EXPRESSION STUDIES

      FEBS letters
    67. Turpin, G; Bruckert, E
      Management of atherogenic hyperlipidaemia.

      ANNALES DE CARDIOLOGIE ET D ANGEIOLOGIE
    68. MULS E; AUTIER P; MALBECQ W; VANSANT G
      CORONARY-HEART-DISEASE RISK-FACTORS AND LDL-CHOLESTEROL-LOWERING EFFICACY OF FIBRATES AND SIMVASTATIN

      Clinical drug investigation
    69. PALMIERI GF; GIOVANNUCCI G; ANTONINI I; MARTELLI S
      INCLUSION COMPLEXATION OF FENOFIBRATE WITH BETA-CYCLODEXTRIN AND HYDROXYPROPYL-BETA-CYCLODEXTRIN EVALUATION OF INTERACTIONS IN SOLUTION ANDSOLID COMPLEX CHARACTERIZATION

      STP pharma sciences
    70. OOI TC; HEINONEN T; ALAUPOVIC P; DAVIGNON J; LEITER L; LUPIEN PJ; SNIDERMAN AD; TAN MH; TREMBLAY G; SORISKY A; SHURZINSKE L; BLACK DM
      EFFICACY AND SAFETY OF A NEW HYDROXYMETHYLGLUTARYL-COENZYME A REDUCTASE INHIBITOR, ATORVASTATIN, IN PATIENTS WITH COMBINED HYPERLIPIDEMIA -COMPARISON WITH FENOFIBRATE

      Arteriosclerosis, thrombosis, and vascular biology
    71. ARNAIZ SL; TRAVACIO M; MONSERRAT AJ; CUTRIN JC; LLESUY S; BOVERIS A
      CHEMILUMINESCENCE AND ANTIOXIDANT LEVELS DURING PEROXISOME PROLIFERATION BY FENOFIBRATE

      Biochimica et biophysica acta. Molecular basis of disease
    72. EBERLEINKONIG B; PLACZEK M; PRZYBILLA B
      PHOTOTOXIC LYSIS OF ERYTHROCYTES FROM HUMANS IS REDUCED AFTER ORAL INTAKE OF ASCORBIC-ACID AND D-ALPHA-TOCOPHEROL

      Photodermatology, photoimmunology & photomedicine
    73. LEROY D; DOMPMARTIN A; SZCZURKO C; MICHEL M; LOUVET S
      PHOTODERMATITIS FROM KETOPROFEN WITH CROSS-REACTIVITY TO FENOFIBRATE AND BENZOPHENONES

      Photodermatology, photoimmunology & photomedicine
    74. STAELS B; SCHOONJANS K; FRUCHART JC; AUWERX J
      THE EFFECTS OF FIBRATES AND THIAZOLIDINEDIONES ON PLASMA TRIGLYCERIDE-METABOLISM ARE MEDIATED BY DISTINCT PEROXISOME PROLIFERATOR ACTIVATEDRECEPTORS (PPARS)

      Biochimie
    75. BOISSONNAT P; DELORGERIL M; PERROUX V; SALEN P; BATT AM; BARTHELEMY JC; BROUARD R; SERRES E; DELAYE J
      A DRUG-INTERACTION STUDY BETWEEN TICLOPIDINE AND CYCLOSPORINE IN HEART-TRANSPLANT RECIPIENTS

      European Journal of Clinical Pharmacology
    76. RASLOVA K; DUBOVSKA D; MONGIELLOVA V; TRNOVEC T
      RELATIONSHIP BETWEEN PLASMA FENOFIBRIC ACID LEVELS AND THE EFFECT OF MICRONIZED FENOFIBRATE ON CHOLESTEROL, LOW-DENSITY-LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN-B IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA

      European Journal of Clinical Pharmacology
    77. SCHAPER J; STEINHAGENTHIESSEN E
      EXPERIENCE WITH HMG-COA-REDUCTASE INHIBIT ORS AND FIBRATES IN THE THERAPY OF COMBINED HYPERLIPIDEMIA

      Die medizinische Welt
    78. FROYLAND L; MADSEN L; VAAGENES H; TOTLAND GK; AUWERX J; KRYVI H; STAELS B; BERGE RK
      MITOCHONDRION IS THE PRINCIPAL TARGET FOR NUTRITIONAL AND PHARMACOLOGICAL CONTROL OF TRIGLYCERIDE-METABOLISM

      Journal of lipid research
    79. TINAHONES JF; PEREZLINDON G; CSORIGUER FJ; PAREJA A; SANCHEZGUIJO P; COLLANTES E
      DIETARY ALTERATIONS IN PLASMA VERY-LOW-DENSITY LIPOPROTEIN LEVELS MODIFY RENAL EXCRETION OF URATES IN HYPERURICEMIC-HYPERTRIGLYCERIDEMIC PATIENTS

      The Journal of clinical endocrinology and metabolism
    80. PETERS JM; HENNUYER N; STAELS B; FRUCHART JC; FIEVET C; GONZALEZ FJ; AUWERX J
      ALTERATIONS IN LIPOPROTEIN METABOLISM IN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA-DEFICIENT MICE

      The Journal of biological chemistry
    81. FOUBERT L; DEJAGER S; BRUCKERT E; TURPIN G
      LIPID RISK-FACTORS OF ATHEROSCLEROSIS - WHO, WHEN AND HOW TO TREAT

      Annales d'Endocrinologie
    82. BRUCKERT E
      TREATMENT OF FAMILIAL COMBINED HYPERLIPIDEMIA

      Annales d'Endocrinologie
    83. PALMIERI GF; ANTONINI I; MARTELLI S
      CHARACTERIZATION AND DISSOLUTION STUDIES OF PEG-4000 FENOFIBRATE SOLID DISPERSIONS

      STP pharma sciences
    84. MCPHERSON R; AGNANI G; LAU P; FRUCHART JC; EDGAR AD; MARCEL YL
      ROLE OF LP A-I AND LP A-I A-II IN CHOLESTERYL ESTER TRANSFER PROTEIN-MEDIATED NEUTRAL LIPID TRANSFER STUDIES IN NORMAL SUBJECTS AND IN HYPERTRIGLYCERIDEMIC PATIENTS BEFORE AND AFTER FENOFIBRATE THERAPY/

      Arteriosclerosis, thrombosis, and vascular biology
    85. YAMAMOTO K; FUKUDA N; ZHANG L; SAKAI T
      ALTERED HEPATIC-METABOLISM OF FATTY-ACIDS IN RATS FED A HYPOLIPEMIC DRUG, FENOFIBRATE

      Pharmacological research
    86. DOSER K; GUSERLE R; NITSCHE V; ARNOLD G
      COMPARATIVE STEADY-STATE STUDY WITH 2 FENOFIBRATE 250-MG SLOW-RELEASECAPSULES - AN EXAMPLE OF BIOEQUIVALENCE ASSESSMENT WITH A HIGHLY VARIABLE DRUG

      International journal of clinical pharmacology and therapeutics
    87. PACKARD CJ
      LDL SUBFRACTIONS AND ATHEROGENICITY - AN HYPOTHESIS FROM THE UNIVERSITY-OF-GLASGOW

      Current medical research and opinion
    88. STEINMETZ A; SCHWARTZ T; HEHNKE U; KAFFARNIK H
      MULTICENTER COMPARISON OF MICRONIZED FENOFIBRATE AND SIMVASTATIN IN PATIENTS WITH PRIMARY TYPE IIA OR IIB HYPERLIPOPROTEINEMIA

      Journal of cardiovascular pharmacology
    89. PEROVA EV; OZEROVA IN; KALININA AM; PAVLOVA LI; OLFERYEV AM; MELKINA OE; GOLUBEV MA; OGANOV RG
      MICRONIZED PHENOFIBRATE ACTION ON PLASMA- LIPOPROTEINS IN VARIOUS BASE-LINE LIPIDS

      Terapevticeskij arhiv
    90. HAHN C; VONBERGMANN K
      RELATIONSHIP BETWEEN THE SERUM CONCENTRATION OF 7-ALPHA-HYDROXYCHOLESTEROL AND FECAL BILE-ACID EXCRETION IN HUMANS

      Scandinavian journal of gastroenterology
    91. BETTERIDGE DJ; OBRYANTEAR CG
      COMPARATIVE EFFICACY AND SAFETY OF CIPROFIBRATE AND SUSTAINED-RELEASEBEZAFIBRATE IN PATIENTS WITH TYPE-II HYPERLIPIDEMIA

      Postgraduate medical journal
    92. SUDHOP T; LUTJOHANN D; RATMAN C; VONBERGMANN J
      DIFFERENCES IN THE RESPONSE OF SERUM-LIPOPROTEINS TO FENOFIBRATE BETWEEN WOMEN AND MEN WITH PRIMARY HYPERCHOLESTEROLEMIA

      European Journal of Clinical Pharmacology
    93. HOFFER MJV; NITHTHYANANTHAN S; NAOUMOVA RP; KIBIRIGE MS; FRANTS RR; HAVEKES LM; THOMPSON GR
      APOLIPOPROTEIN EL-HAMMERSMITH (LYS146-]ASN-ARG147-]TRP), DUE TO A DINUCLEOTIDE SUBSTITUTION, IS ASSOCIATED WITH EARLY MANIFESTATION OF DOMINANT TYPE-III HYPERLIPOPROTEINEMIA

      Atherosclerosis
    94. DESAGER JP; HORSMANS Y; VANDENPLAS C; HARVENGT C
      PHARMACODYNAMIC ACTIVITY OF LIPOPROTEIN-LIPASE AND HEPATIC LIPASE, AND PHARMACOKINETIC PARAMETERS MEASURED IN NORMOLIPIDEMIC SUBJECTS RECEIVING CIPROFIBRATE (100 OR 200 MG DAY) OR MICRONIZED FENOFIBRATE (200 MG/DAY) THERAPY FOR 23 DAYS/

      Atherosclerosis
    95. KNIPSCHEER HC; DEVALOIS J; VANDENENDE B; TENCATE JW; KASTELEIN JJP
      CIPROFIBRATE VERSUS GEMFIBROZIL IN THE TREATMENT OF PRIMARY HYPERLIPIDEMIA

      Atherosclerosis
    96. TURPIN G; BRUCKERT E
      EFFICACY AND SAFETY OF CIPROFIBRATE IN HYPERLIPOPROTEINEMIAS

      Atherosclerosis
    97. STEINER G
      THE DIABETES ATHEROSCLEROSIS INTERVENTION STUDY (DAIS) - A STUDY CONDUCTED IN COOPERATION WITH THE WORLD-HEALTH-ORGANIZATION

      Diabetologia
    98. CANUDAS N; VARGAS F; MIRANDA MA
      PHOTODEGRADATION OF BEZAFIBRATE IN AQUEOUS-MEDIA - STUDIES OF ITS IN-VITRO PHOTOTOXICITY

      Arzneimittel-Forschung
    99. MULS E; HOFMANS E; DROUSSIN AM; VERCAMMEN C; VANSANT G
      SEQUENTIAL MANAGEMENT OF HYPERCHOLESTEROLEMIA WITH A FIBRATE AND SIMVASTATIN - THE BELGIAN GENERAL-PRACTITIONERS TRIAL

      Clinical drug investigation
    100. MARGUERY MC; ELSAYED F; RAKOTONDRAZAFY J; SAQI R; SAMALENS G; GORGUET B; BAZEX J
      PHOTOALLERGY AND PHOTOAGGRAVATION INDUCED BY FENOFIBRATE - CROSS-PHOTOREACTION AND TRANSIENT LIGHT REACTION

      EJD. European journal of dermatology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/08/20 alle ore 14:59:47